Opportunity ID: 285611

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-351
Funding Opportunity Title: Conference for Early Stage HIV/AIDS Vaccine Researchers (R13)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.351 — Research Infrastructure Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jun 30, 2016
Last Updated Date:
Original Closing Date for Applications: Sep 06, 2016
Current Closing Date for Applications: Sep 06, 2016
Archive Date: Oct 07, 2016
Estimated Total Program Funding:
Award Ceiling: $100,000
Award Floor:

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See FOA for Eligibility Details

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct intensive workshop/conference/meeting(s) that address the needs of early stage HIV/AIDS vaccine researchers as they translate preclinical research from nonhuman primates (NHPs) to human clinical trials. The objectives of the meeting supported by this FOA are to provide these early stage HIV/AIDS vaccine researchers with guidance on conducting preclinical research to inform HIV vaccine strategies for clinical trials and developing skills related to networking, work-life balance, grantsmanship, and goal/milestone-oriented projects. Conference topics should include, but not be limited to: critical aspects of human vaccine development, including statistical considerations, host genetics and others; methods to translate the results of NHP challenge studies to clinical trials in humans; and methods to develop milestone-driven projects.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-351.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-D Use for due dates on or after May 25, 2016 PKG00225128 Aug 06, 2016 Sep 06, 2016 View

Package 1

Mandatory forms

285611 RR_SF424_2_0-2.0.pdf

285611 PHS398_CoverPageSupplement_3_0-3.0.pdf

285611 RR_OtherProjectInfo_1_3-1.3.pdf

285611 PerformanceSite_2_0-2.0.pdf

285611 RR_KeyPersonExpanded_2_0-2.0.pdf

285611 RR_Budget_1_3-1.3.pdf

285611 PHS398_ResearchPlan_3_0-3.0.pdf

Optional forms

285611 RR_SubawardBudget30_1_3-1.3.pdf

285611 PHS_Inclusion_Enrollment_Report-1.0.pdf

285611 PHS_AssignmentRequestForm-1.0.pdf

2025-07-09T16:12:07-05:00

Share This Post, Choose Your Platform!

About the Author: